Medical Oncologist
Bone health
Stopping and restarting bone-directed therapy
Bisphosphonates keep working after they stop, but denosumab's effect wears off within months, and stopping it without a plan can cause rapid bone loss and spinal fractures. This page explains, in general terms, how bone medicines are stopped and restarted safely.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
On this page
- What happens when bone-directed treatment is stopped?
- Stopping bisphosphonates and denosumab, in general terms
- How denosumab is usually stopped safely
- The vocabulary, in plain language
- What we know about stopping bone medicines
- Why bone-directed treatment might be stopped
- Staying on schedule with denosumab
- Why bone loss can speed up after stopping denosumab
- When bone treatment needs to start again
- Planned breaks from bisphosphonates
- What people assume about stopping bone medicines
- Common questions about stopping and restarting bone medicines
The short answer
What happens when bone-directed treatment is stopped?
It depends on the medicine. Bisphosphonates such as zoledronic acid and alendronate bind to bone and keep working for months or years after the last dose, so stopping them gradually allows bone turnover to return towards normal. Denosumab is different. Its effect wears off within months, and when it stops, bone breakdown can increase sharply, faster than before treatment began. This rebound can cause rapid bone loss and, in some people, several spinal fractures within a year of stopping. For this reason, denosumab should not be stopped or delayed without a plan, and a bisphosphonate is usually given afterwards to hold on to the bone that was gained.
Why denosumab behaves differently
Denosumab blocks a signal needed to form bone-breaking cells. When the block lifts, a large number of these cells form at once and break down bone quickly.
The usual safe approach
When denosumab is to end, a bisphosphonate such as zoledronic acid or alendronate is given around the time the next denosumab dose would have been due, sometimes with repeat doses guided by bone tests.
Restarting treatment
Bone medicines can often be restarted if bone density falls again or treatment is needed for bone metastases. Your team plans timing to maintain protection.
This page gives general information only. Never stop denosumab without speaking to your team.Side by side
Stopping bisphosphonates and denosumab, in general terms
Bisphosphonates
Denosumab
Effect lasts long after stopping
Effect wears off within months
No rapid rebound
Risk of rapid rebound bone loss
Planned breaks sometimes used
Breaks are not recommended without follow-on treatment
Restart based on bone checks
Follow-on bisphosphonate usually needed
Stopping safely
How denosumab is usually stopped safely
Discuss the plan early
Talk with your team well before the final planned dose about why and how treatment will end.
Check bone health
A bone density scan and sometimes blood tests of bone turnover guide the plan.
Start a follow-on bisphosphonate
Usually given around the time the next denosumab dose would have been due.
Monitor afterwards
Repeat tests or scans check that bone density is being maintained.
Repeat if needed
Further bisphosphonate doses may be given based on test results.
Words you will hear
The vocabulary, in plain language
- Rebound bone loss
- Rapid bone loss after stopping denosumab.
- Multiple vertebral fractures
- Several breaks in spinal bones, a risk after stopping denosumab suddenly.
- Bone turnover markers
- Blood tests showing how quickly bone is being broken down and rebuilt.
- Drug holiday
- A planned pause in treatment, sometimes used with bisphosphonates.
- Follow-on therapy
- A medicine given after stopping denosumab to prevent rebound.
- Alendronate
- A bisphosphonate tablet taken weekly.
Being straight with you
What we know about stopping bone medicines
The rebound effect after stopping denosumab is well recognised, and guidelines now stress the importance of planned transitions. The best follow-on schedule is still being studied, so plans are tailored to each person.
Missed doses matter
Delays of more than a few weeks beyond a scheduled denosumab dose can start the rebound process. If a dose is late, contact your team promptly.
Bisphosphonate breaks are different
With bisphosphonates, planned breaks after several years are sometimes used for osteoporosis, because their effect persists. Decisions depend on bone density and fracture risk.
Cancer treatment may change the plan
If bone metastases develop, bone medicines are usually restarted or continued at doses suited to that situation.
What this page cannot tell you
It cannot plan your transition. Ask your team how and when your treatment should change.
Reasons for change
Why bone-directed treatment might be stopped
There are several common reasons your team might plan to stop or change bone medicines.
Hormone therapy has finished
When aromatase inhibitors end, the main cause of accelerated bone loss is removed, and bone medicine may no longer be needed.
Side effects
Low calcium, jaw problems or other side effects may lead to a change of treatment.
Cost or access
If denosumab becomes unaffordable, tell your team before missing doses, so a safe switch to a bisphosphonate can be arranged.
Planned dental surgery
Occasionally treatment timing is adjusted around unavoidable dental procedures.
Talk to our team
Have a question about your situation?
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Practical points
Staying on schedule with denosumab
Keeping injections on time is the simplest way to avoid rebound problems.
Keep a dose calendar
Write down the date of each injection and when the next one is due, and set a phone reminder.
Book ahead
Arrange the next appointment before leaving the clinic, especially around holidays or travel.
Plan around travel and festivals
Long trips, weddings and festival seasons are easy times for a dose to slip. If you know you will be away, ask whether the injection can be given a little earlier, or arrange for it to be given at a centre where you will be staying.
Carry information
Keep a card noting that you receive denosumab, in case you see other doctors.
Understanding rebound
Why bone loss can speed up after stopping denosumab
The rebound effect is not simply the medicine stopping working. Bone turnover actually increases above where it was before treatment, for a period.
A build-up of bone-breaking cells
While denosumab is active, it blocks the signal that forms osteoclasts, the cells that break down bone. Cells that would normally have become osteoclasts accumulate in a waiting state.
What happens when the block lifts
When denosumab wears off, these cells mature together, and bone breakdown surges. Bone density gained during treatment can be lost within a year or two.
Why the spine is most affected
The spongy bone of the spine is renewed quickly, so it loses strength fastest during rebound. This is why multiple spinal fractures are the main concern.
How bisphosphonates help
A bisphosphonate given at the right time binds to bone and dampens this surge in breakdown, protecting much of the bone that was gained.
Restarting
When bone treatment needs to start again
Stopping bone treatment is not always permanent. Several situations can lead your team to restart it.
Bone density falls again
Repeat scans may show bone thinning returning, particularly if hormone therapy continues or menopause-related bone loss progresses.
A new fracture
A fracture from a minor fall usually prompts review and often restarting treatment.
Bone metastases
If cancer spreads to bone, bone medicines are usually restarted at doses suited to protecting the skeleton from complications.
Bisphosphonate breaks
Planned breaks from bisphosphonates
Because bisphosphonates remain in bone, doctors sometimes recommend a planned break after several years of treatment for osteoporosis.
Who may be offered a break
People whose bone density has improved and whose fracture risk is now lower may pause treatment while being monitored.
Why breaks are used
Long-term use carries rare risks, such as unusual thigh bone fractures and jaw problems. A break can lower these while the drug's effect persists.
Monitoring during a break
Repeat scans and sometimes blood tests show when treatment should resume.
Commonly believed
What people assume about stopping bone medicines
All bone medicines can be stopped the same way.
Denosumab needs a planned transition; bisphosphonates do not rebound in the same way.
A few months' delay in denosumab does not matter.
Delays can trigger rapid bone loss. Keep doses on time.
Once bones are strong, I can just stop.
Bone gained on denosumab can be lost quickly without follow-on treatment.
Bone medicines can never be restarted.
They can often be restarted if needed, with careful planning.
Questions we are asked
Common questions about stopping and restarting bone medicines
What if I have already missed a denosumab dose?
Contact your team as soon as possible. They may give the dose promptly or start a bisphosphonate to reduce rebound risk.
Which bisphosphonate follows denosumab?
Often zoledronic acid or alendronate. Your team chooses based on your health.
How long does follow-on treatment last?
It varies, often guided by bone density and turnover tests.
Can I switch from zoledronic acid to denosumab?
Yes, if needed, but plan for how denosumab will eventually end.
Do bisphosphonates need a follow-on medicine?
Usually not, because their effect lasts after stopping.
What symptoms suggest a spinal fracture?
Sudden back pain, height loss or a stoop. Report these promptly.
Can cost problems be solved without stopping?
Ask about biosimilars or switching to a lower-cost bisphosphonate safely.
Where can I read about my own treatment?
Your oncology team will give you written information about your treatment. Use that as your main reference.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Warangal
Vizag
Talk to our team
Speak to a breast cancer specialist
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Sources
- European Calcified Tissue Society — Position statement on denosumab discontinuation
- American Society of Clinical Oncology — Management of osteoporosis in survivors of adult cancers with nonmetastatic disease
- Cancer Research UK — Denosumab (Xgeva, Prolia)
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.